Predictability study of the pharmacodynamic properties of drugs in silico by the example of comparing data on the naphazoline clinical use and the results of computer modeling

Abstract

The forecast of naphazoline pharmacological properties has been made using the PASS computer program and the ADVER-Pred web resource of the Way2Drug information and computing platform. Biological activity, mechanisms of action, toxic and side effects, as well as other types of activity of the studied drug associated with interaction with antitargets, metabolism and gene expression regulation have been determined. The results of the naphazoline pharmacological properties forecast obtained in silico have been compared with the information available in the literature about its systemic effects in clinical use and poisoning.It has been established that the studied chemical compound has a very wide spectrum of action, which is primarily associated with the stimulation of adrenoreceptors and imidazoline receptors located in many organs and tissues of the body. At the same time, other mechanisms of naphazoline action forecasted in silico allow us to determine possible directions for further research of its clinical use. Among the toxic and side effects, along with such known adverse events as effect on the central nervous system and arterial hypertension, in the clinical use of naphazoline special attention should be paid to the cardio-, hepato- and nephrotoxic effects forecasted with a high degree of probability. The prominent toxic effect of naphazoline can cause the occurrence of life- threatening conditions - acute cerebrovascular disorder, myocardial infarction, cardiac rhythm disorders, acute left ventricular failure. The obtained data confirm that the use of modern computer methods that provide an assessment of biological activity based on the drug-like compound graphic formula allows us to obtain a forecast with a high degree of confidence for both new pharmacological substances and for drugs approved for clinical use in order to clarify their pharmacological properties.

Keywords

naphazoline / biological activity / mechanisms of action / toxic and side effects / clinical use / poisoning / computer resources / drug development / computer-aided prediction

References

[1] Варвянская, А.В. Топические назальные деконгестанты: сравнительная характеристика и обзор побочных эффектов / А.В. Варвянская, А.С. Лопатин // Росс. ринология. – 2015. – № 4. – С. 50–56.

[2] Владимиров, В.Г. Радиопротекторы: структура и функция / В.Г. Владимиров, И.И. Красильников, О.В. Арапов. – Киев: Наук. думка, 1989. – 264 с.

[3] Лекарственные средства, применение которых может вызвать развитие или утяжеление сердечной недостаточности: основные положения заявления экспертов Американской ассоциации кардиологов (часть III) // Доказательная кардиология. – 2017. – № 1. – С. 26–40.

[4] Машковский, М.Д. Лекарственные средства. – 16-е изд., перераб., испр. и доп. / М.Д. Машковский. – М.: Новая волна: Издатель Умеренков, 2019. – 1216 с.

[5] Поройков, В.В. Компьютерное конструирование лекарств: от поиска новых фармакологических веществ до системной фармакологии / В.В. Поройков // Биомед. химия. – 2020. – Т. 66, вып. 1. – С. 30–41.

[6] Промышленная фармация. Путь создания продукта: монография / Ж.И. Аладышева [и др.]; под ред. А.Л. Хохлова и Н.В. Пятигорской. – М., 2019. – 394 с.

[7] Пшеничная, Е.В. Деконгестанты и их побочные действия в лечении острого ринита у детей (клинический пример) / Е.В. Пшеничная, А.П. Дудчак, Н.А. Усенко // Мать и дитя в Кузбассе. – 2018. – № 3. – С. 50–53.

[8] Рехарская, Е.М. Фосфоресценция некоторых лекарственных препаратов нафталинового ряда в водных средах / Е.М. Рехарская, Т.В. Поленова, А.Г. Борзенко // Вестн. Московского университета. Серия 2: Химия. – 2004. – Т. 42, № 5. – С. 112–116.

[9] Тришкин, Д.В. Современное состояние и перспективы развития персонализированной медицины, высокотехнологичного здравоохранения и технологий здоровьесбережения в медицинской службе Вооруженных сил Российской Федерации / Д.В. Тришкин [и др.] // Вестн. Росс. воен.-мед. акад. – 2019. – № 3 (67). – С. 145–150.

[10] Тулупов, Д.А. Современные аспекты применения назальных сосудосуживающих и вспомогательных препаратов в педиатрической практике / Д.А. Тулупов // Мед. совет. – 2018. – № 2. – С. 114–117.

[11] Федоров, Д.Б. Исследование препарата нафтизин в вещественных доказательствах и биологических жидкостях / Д.Б. Федоров, С.В. Волченко, В.Н. Куклин // Суд.-мед. экспертиза. – 2013. – № 5. – С. 29–33.

[12] Филимонов, Д.А. Компьютерное прогнозирование спектров биологической активности химических соединений: возможности и ограничения / Д.А. Филимонов [и др.] // Biomedical Chemistry: Research and Methods. – 2018. – Т. 1, № 1. – С. 1–21.

[13] 13.Chapman, R.A. Which of caffeine’s chemical relatives are able to evoke contractures in mammalian heart? / R.A. Chapman, C. Leoty // Recent advances in studies on cardiac structure and metabolism. – 1975. – № 7. – P. 425–430.

[14] Corboz, M.R. Mechanism of decongestant activity of α2adrenoceptor agonists / M.R. Corboz [et al.] // Pulmonary Pharmacology & Therapeutics. – 2008. – Vol. 21, Issue 3. – P. 449–454.

[15] Costantino, G. Ischemic stroke in a man with naphazoline abuse story / G. Costantino [et al.] // American Journal of Emergency Medicine. – 2007. – Vol. 25, № 8. – P. 983.

[16] Di Lorenzo, C. Nasal decongestant and chronic headache: a case of naphazoline overuse headache? / C. Di Lorenzo [et al.] // F1000Research. – 2013. – № 2. – P. 237.

[17] Di Masi, J.A. Innovation in the pharmaceutical industry: New estimates of R&D costs / J.A. Di Masi, H.G. Grabowski, R.W. Hansen // J. Health Econ. – 2016. – № 47. – Р. 20–33.

[18] Filimonov, D. Chemical similarity assessment through multilevel neighborhoods of atoms: definition and comparison with the other descriptors / D. Filimonov [et al.] // J. Chem. Inf. Comput. Sci. – 1999. – № 39 (4). – Р. 666–670.

[19] Fukushima, H. Acute pulmonary edema associated with naphazoline ingestion / H. Fukushima [et al.] // Clinical Toxicology (Phila). – 2008. – Vol. 46, № 3. – P. 254–256.

[20] Gollоm, J. The problem of nasal medication with particular reference to Privine HCL 0.1% / J. Gollоm // Canadian Medical Association Journal. – 1944. – Vol. 51, № 2. – P. 123–126.

[21] Hainsworth, W.C. Accidental poisoning with naphazoline («PRIVINE») hydrochlorid / W.C. Hainsworth // American Journal of Diseases of Children. – 1948. – Vol. 75, № 1. – P. 76–80.

[22] Hünerman, T. Kritisches zur Schnupfentherapie / T. Hünerman // Deutsche Medizinische Wochenschrift. – 1942. – Bd. 68. – S. 580–581.

[23] Ivanov, S.M. ADVERPred – web service for prediction of adverse effects of drugs / S.M. Ivanov [et al.] // Journal of Chemical Information and Modeling. – 2018. – № 58 (1). – Р. 8–11.

[24] Johnson, D.A. The pharmacology of alpha-adrenergic decongestants / D.A. Johnson, J.G. Hricik // Pharmacotherapy. – 1993. – Vol. 13, № 6. – Pt. 2. – P. 110–115.

[25] Kuzminov, B. Rationale for naphazoline effects in-depth study / B. Kuzminov, V. Turkina, Y. Kuzminov // Current Issues in Pharmacy and Medical Sciences. – 2018. – Vol. 39, № 1. – P. 29–33.

[26] Lowry, J.A. Significance of the imidazoline receptors in toxicology / J.A. Lowry, J.T. Brown // Clinical Toxicology. – 2014. – Vol. 52, № 5. – P. 454–469.

[27] Masasi, F. Research on chemical antiradiation protection in Japan / F. Masasi // Strahlentherapie. – 1962. – Bd. 117, № 1. – Р. 142–146.

[28] McEvoy, G.K. AHFS Drug information 2006. Naphazoline hydrochloride / G.K. McEvoy // Bethesda: American Society of Health-System Pharmacists. – 2006. – P. 2827–2828.

[29] McGrath, J.C. Localization of α-adrenoceptors: JR Vane Medal Lecture / J.C. McGrath // British journal of pharmacology. – 2015. – Vol. 172, № 5. – P. 1179–1194.

[30] Mourret, A. Etude de l’efficacite de trois heterocyles azotes radioprotecteurs sur des souris c3h irradiees au cobalt 60 / A. Mourret, C. Agnius, R. Rinaldi // Comptes rendus de l’Académie des Sciences. – 1972. – Vol. 275, № 14. – P. 1575–1578.

[31] Ono, Y. Tissue hypoperfusion, hypercoagulopathy, and kidney and liver dysfunction after ingestion of a naphazoline-containing anti-septic / Y. Ono, N. Ono, K. Shinohara // Case reports in emergency medicine. – 2017. – Vol. 2017. – Article ID 3968045. – 5 р.

[32] Prouillac, C. Evaluation, in vitro, of the radioprotection of DNA from é-rays by naphazoline / C. Prouillac [et al.] // – Comptes Rendus Biologies. – 2006. – Vol. 329, Issue 3. – P. 196–199.

[33] Ramey, J.T. Rhinitis medicamentosa / J.T. Ramey, E. Bailen, R.F. Lockey // Journal of Investigational Allergology and Clinical Immunology. – 2006. – Vol. 16, № 3. – P. 148–155.

[34] Ruffolo, R.R. Distribution and function of peripheral α-adrenoceptors in the cardiovascular system / R.R. Ruffolo // Pharmacology Biochemistry and Behavior. – 1985. – Vol. 22, № 5. – P. 827–833.

[35] Sarchielli, P. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks / P. Sarchielli [et al.] // Cephalalgia. – 2000. – Vol. 20, № 10. – P. 907–1018.

[36] Wenzel, S. Course and therapy of intoxication with imidazoline derivate naphazoline / S. Wenzel [et al.] // Int. J. Pediatr. Otorhinolaryngol. – 2004. – Vol. 68, № 7. – P. 979–983.

[37] Willems, E.W. Possible role of alpha-adrenoceptor subtypes in acute migraine therapy / E.W. Willems [et al.] // Chephalalgia. – 2003. – Vol. 23, № 4. – P. 245–257.

[38] Zavala, J.A.A. Hemorrhagic stroke after naphazoline exposition: case report / J.A.A. Zavala [et al.] // Arquivos de NeuroPsiquiatria. – 2004. – Vol. 62, № 3-B. – P. 889–891.

RIGHTS & PERMISSIONS

Ivanov V.S., Seleznev A.B., Ivchenko E.V., Cherkashin D.V., Kutelev G.G., Boyko Y.G.